StockData

Alector vs Denali Therapeutics

ALEC and DNLI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALEC and DNLI compare

Denali Therapeutics is the larger company, worth 11 times as much as Alector ($3.0B against $274M).

Alector scores higher on the StockData Score (12 against 6 for Denali Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALECDNLI
Size and price
Market cap$274M$3.0B
Share price$2.45$18.89
Change, 1 year80.1%7.5%
Change, 5 years−88.5%−59.9%
Beta (5Y)1.501.66
Employees103503
StockData Score
Total score12 (better)6
Valuation score3 (better)0
Growth score1 (better)0
Performance score3 (better)1
Health score55
Dividend score00
Valuation
P/E7.0×–
P/S1.6×–
P/B2.3× (better)3.6×
EV/EBITDA3.4×–
FCF yield−54.8%−14.5% (better)
Fair value$8.03–
Margin of safety69.5%–
Growth
Revenue growth (TTM)151%–
Revenue growth, 5Y average−0.05%–
Profitability
Operating margin20.2%–
Net margin23.9%–
FCF margin−86.5%–
Return on equity47.5% (better)−54.9%
Return on invested capital–−343%
Financial health
Debt / equity0.000.00
Net debt / EBITDA−3.53–
Current ratio4.108.37 (better)
Altman Z-score−1.671.96 (better)
Piotroski F-score13 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions85.8%97.7%
Held by insiders9.6%6.6%
Insider net buying, 12 months−$1.0M (better)−$1.3M
Short interest, % of float8.3%9.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.